Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
PB PER.C6® Licensing Agreement with UMN Phar
Volgen
Kom net weer thuis na kort weekje buitenland is dit wel gepost 2 november? DSM Biologics Will Produce UMN Pharma’s Diabetes Treatment Nov 2 2006, 2:34 PM EST GEN News Highlights DSM Biologics and UMN Pharma signed a biopharmaceutical manufacturing agreement based on Crucell’s PER.C6® manufacturing platform. DSM Biologics will provide UMN Pharma with process development services, analytical development services, and cGMP manufacturing for UMN Pharma’s UMN-03 fusion protein. UMN Pharma developed the UMN-03 fusion protein for the treatment of muscular dystrophy and metabolic diseases, such as obesity and type 2 diabetes. The services will be provided out of DSM Biologics’ manufacturing facility in Groningen. The Agreement follows the license agreement that was signed in March, 2006 between UMN Pharma, DSM Biologics, and Crucell.www.genengnews.com/news/bnitem.aspx?n...
Press release DSM Pharmaceutical Products November 2, 2006 45 Waterview Blvd Parsippany, NJ 07054-1298 DSM Biologics and UMN Pharma Inc. Sign a Biopharmaceutical Manufacturing Agreement based on the PER.C6® Manufacturing Platform Parsippany, November 2, 2006 DSM Biologics (headquartered in Parsippany, NJ) and UMN Pharma, Inc. (headquartered in Akita, Japan) have signed a Biopharmaceutical Manufacturing Agreement based on the PER.C6® Manufacturing Platform. Under the terms of the Agreement DSM Biologics will provide UMN Pharma with (a) full process development services, (b) full analytical development services and (c) cGMP manufacturing batches for UMN Pharma’s UMN-03 fusion protein. UMN Pharma develops the UMN-03 fusion protein for the treatment of muscular dystrophy and metabolic diseases such as obesity and type II diabetes mellitus. The services will be provided out of DSM Biologics’ FDA-approved manufacturing facility in Groningen. The Agreement follows the License Agreement that was signed in March this year between UMN Pharma, DSM Biologics and Crucell. Both parties are very pleased with the results of the collaboration to date. “The Agreement builds further on the PER.C6® License Agreement that is in place between UMN Pharma, DSM Biologics and Crucell. We gladly entrust DSM Biologics with the execution of this Manufacturing Agreement that is crucial for the success of our UMN-03 fusion protein” says Yasunari Kashihara, President & CEO of UMN Pharma, Inc. “DSM Biologics is very happy to be involved in this exciting project. The agreement is a further example of the broad use of the PER.C6® manufacturing platform. It is also a clear recognition of the value that DSM Biologics and the PER.C6® manufacturing platform are expected to bring to UMN Pharma, an important client for DSM Biologics” says Terry Novak, Business Director and Chief Marketing Officer for DSM Biologics. About DSM Biologics DSM Biologics, a business unit of DSM Pharmaceutical Products, is a leading provider of manufacturing technology & services to the biopharmaceutical industry. In addition to offering world-class biopharmaceutical manufacturing services, DSM Biologics has co-exclusive rights, along with Dutch biotech company Crucell N.V., to license the high-producing PER.C6® human cell line as a production platform for recombinant proteins and monoclonal antibodies. DSM Biologics’ FDA-approved facility in Groningen, the Netherlands was established in 1986, and has a strong track record in using a broad range of cell lines (PER.C6®, CHO, hybridoma, etc.) in biopharmaceutical manufacturing, and has a wide-range of experience using multiple manufacturing (batch, fed-batch and continuous perfusion) and purification techniques. The combination of the PER.C6® human cell line and DSM’s manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market. DSM Biologics is being represented Press release in Japan by Asahi Glass & Co., Ltd. For more information, please visit www.dsmbiologics.com. About UMN Pharma UMN Pharma, a pharmaceutical company, is dedicated to developing innovative disease preventives and therapeutics to satisfy unmet medical needs. UMN’ leverages extensive pharmaceutical industry experience to generate time-efficient, focused development plans followed by rapid preclinical and clinical development to meet both Japanese and international regulatory specifications. UMN has a diverse pipeline of novel small molecule and protein drug candidates targeted to cancer, diabetes and other major therapeutic markets. Four products are currently in preclinical development with the first clinical study scheduled for early 2007. UMN anticipates that four products will be in the clinical stage within a two-year timeframe. For more information, please visit www.umnpharma.com. For more information: DSM Pharmaceutical Products Terry Novak Chief Marketing Officer 973-257-8471 Terry.Novak@dsm.com DSM Biologics Marcel Lubben Manager, New Business Development Europe & Asia +31 46 47 73343 Marcel-m.lubben@dsm.com DSM Biologics Brad Carlson Vice President, Marketing, Sales & NBD Tel. +1 (585) 624-3844 Brad.Carlson@dsm.com UMN Pharma, Inc. Yasunari Kashihara President & CEO +81 (3) 5728-5420ykashihara@umnpharma.com
gocrucellgo schreef:
Kom net weer thuis na kort weekje buitenland is dit wel gepost 2 november?
Stelletje slaapkoppen hier.... mooi go, ab!
AB verdiend Go! Goed speurwerk.
Ik vind wel dat Crucell hier toch ook wel een PB'tje aan had kunnen wijden. Crucell had toch beloofd elke voortgang te melden, betrekking hebbende op clinical trials betreffende PerC6, STAR etc. ??? Dirk
Cybertom schreef:
AB verdiend Go! Goed speurwerk.
En wellicht een verklaring voor de grote hap in VS rond die tijd gisteren?
flosz schreef:
[quote=gocrucellgo]
Kom net weer thuis na kort weekje buitenland is dit wel gepost 2 november?
[/quote]
Stelletje slaapkoppen hier....
mooi go, ab!
Fundamenteel weer een mooi dagje vandaag voor Crucell. Goed gevonden!
Go-go-go GO en kom nog maar vaker ZO thuis!
We plan to start the first clinical study in early 2008. ************************* UMN-03 UMN-03 is a recombinant fusion protein, which neutralizes endogenous myostatin (growth and differentiation factor 8 or GDF-8), a protein whose role is to reduce the amount of muscle tissue that is formed. Substantial published data indicate that blocking the action of myostatin can promote extra muscle growth, thus providing potential therapeutic advantage for patients with muscular dystrophy. Furthermore, UMN-03 can reduce fat tissue and could thereby provide a new therapeutic approach for type II diabetes or obesity. We plan to start the first clinical study in early 2008. umnpharma.com/eng/pipeline.html#EXP
DSM and UMN sign manufacturing deal by Emilie Reymond Get the latest Market Reports on DSM Biologics UMN Pharma PER.C6 Related News Crucell moves PER.C6 into Canada Crucell/DSM push PER.C6 technology forward 09/11/2006 - DSM Biologics, the biopharma arm of DSM group, has signed a manufacturing deal with Japanese UMN Pharma based on the firm’s novel recombinant protein manufacturing platform. Under the terms of the agreement, the contract manufacturer will provide UMN with full process and analytical development services and cGMP manufacturing batches for its recombinant fusion protein, UMN-03, using DSM's PERC6 cell line platform. UMN-03 is a myostatin-inhibiting fusion protein aimed at the treatment of muscular dystrophy and metabolic diseases such as obesity and type II diabetes mellitus. After finishing the manufacture of the clinical sample, the clinical study will be started in 2008, UMN said. Dutch company DSM has co-exclusive rights, along with another Dutch biotech company, Crucell, to license the high-producing PER.C6 human cell line as a production platform for recombinant proteins and monoclonal antibodies. The PER.C6 technology uses cell culture for the large-scale production of recombinant proteins and monoclonal antibodies, including influenza vaccine, where the virus is grown on specially selected cell lines instead of chicken eggs. The strengths of the PER.C6 technology lie in its safety profile, scalability and productivity under serum-free culture conditions. This cell culture process has the potential to reduce from four weeks to two or three weeks the start-up time for manufacturing and could result in a more predictable manufacturing process. This latest agreement builds further on the PER.C6 license agreement that was signed in March between UMN Pharma, DSM Biologics and Crucell. "The protein market is growing rapidly and may reach $200bn (€157bn) in 15 to 20 years and we believe that PER.C6 has the potential to become the technology of choice for an attractive part of that market," said Leendert Staal, president of DSM pharmaceutical products. The services will be provided out of DSM Biologics' FDA-approved manufacturing facility in Groningen, Netherlands. www.in-pharmatechnologist.com/news/ng...
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Indices
AEX
887,44
+0,99%
EUR/USD
1,0763
-0,02%
FTSE 100
8.213,49
+0,51%
Germany40^
18.017,10
+0,09%
Gold spot
2.310,09
+0,36%
NY-Nasdaq Composite
16.156,33
+1,99%
Stijgers
Dalers